Nogueira-Costa R, Spitzer G, Khorana S, Pham Q, Kantarjian H M, Manning J T, Ordonez N G, Dicke K A
Leuk Res. 1986;10(12):1433-9. doi: 10.1016/0145-2126(86)90010-x.
T cells from the peripheral blood of patients with chronic myeloid leukemia (CML) were cultured with phytohemagglutinin and T-cell growth factor (TCGF) in agar culture. These T-cell colonies were pooled and expanded further in liquid culture with TCGF and then simultaneously analysed for the E-rosette receptor with the monoclonal antibody OKT11 and for the presence of the Philadelphia (Ph1) chromosome. OKT11 analysis showed these populations to be composed 99.5% or more of T cells. In four of the seven patients the T-cell suspension showed 7/50 (14%), 3/36 (8%), 2/34 (6%), and 4/44 (9%) Ph1 metaphases. Furthermore, Ph1 metaphases were demonstrated in T-cell cultures in two patients when bone marrow metaphases simultaneously showed 90 and 100% Ph1 negative metaphases secondary to human leukocyte interferon therapy or combination chemotherapy. A minority of T cells in benign phase CML have the Ph1 abnormality despite reduced number of Ph1 metaphases in bone marrow from therapy.
将慢性髓性白血病(CML)患者外周血中的T细胞与植物血凝素和T细胞生长因子(TCGF)在琼脂培养中进行培养。将这些T细胞集落汇集起来,并用TCGF在液体培养中进一步扩增,然后同时用单克隆抗体OKT11分析E玫瑰花结受体,并检测费城(Ph1)染色体的存在情况。OKT11分析显示这些细胞群中T细胞占99.5%或更多。在7例患者中的4例中,T细胞悬液显示有7/50(14%)、3/36(8%)、2/34(6%)和4/44(9%)的Ph1中期细胞。此外,在两名患者的T细胞培养物中发现了Ph1中期细胞,而此时骨髓中期细胞在人白细胞干扰素治疗或联合化疗后同时显示90%和100%的Ph1阴性中期细胞。尽管治疗后骨髓中Ph1中期细胞数量减少,但处于慢性髓性白血病良性期的少数T细胞仍存在Ph1异常。